Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nature Biotechnology's academic spinouts of 2013.

Literature DB >> 24727773

Nature Biotechnology's academic spinouts of 2013.

Aaron Bouchie, Malorye Allison, Sarah Webb, Laura DeFrancesco¹.
1. Nature Biotechnology.

Abstract

Mesh：

Substances：
Proteins

Year: 2014 PMID： 24727773 DOI： 10.1038/nbt.2846

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

26 in total

1. Super-enhancers in the control of cell identity and disease.

Authors: Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal: Cell Date: 2013-10-10 Impact factor: 41.582

2. Inhibitor mediated protein degradation.

Authors: Marcus J C Long; Deviprasad R Gollapalli; Lizbeth Hedstrom
Journal: Chem Biol Date: 2012-05-25

3. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal: Blood Date: 2010-07-28 Impact factor: 22.113

4. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors: Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956

5. Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors: Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal: Cell Date: 2013-04-11 Impact factor: 41.582

6. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.

Authors: Dennis L Buckley; Jeffrey L Gustafson; Inge Van Molle; Anke G Roth; Hyun Seop Tae; Peter C Gareiss; William L Jorgensen; Alessio Ciulli; Craig M Crews
Journal: Angew Chem Int Ed Engl Date: 2012-10-12 Impact factor: 15.336

7. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.

Authors: Aude G Chapuis; Gunnar B Ragnarsson; Hieu N Nguyen; Colette N Chaney; Jeffrey S Pufnock; Thomas M Schmitt; Natalie Duerkopp; Ilana M Roberts; Galina L Pogosov; William Y Ho; Sebastian Ochsenreither; Matthias Wölfl; Merav Bar; Jerald P Radich; Cassian Yee; Philip D Greenberg
Journal: Sci Transl Med Date: 2013-02-27 Impact factor: 17.956

8. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Authors: Carolina Berger; Michael C Jensen; Peter M Lansdorp; Mike Gough; Carole Elliott; Stanley R Riddell
Journal: J Clin Invest Date: 2008-01 Impact factor: 14.808

9. Defining the core Arabidopsis thaliana root microbiome.

Authors: Derek S Lundberg; Sarah L Lebeis; Sur Herrera Paredes; Scott Yourstone; Jase Gehring; Stephanie Malfatti; Julien Tremblay; Anna Engelbrektson; Victor Kunin; Tijana Glavina Del Rio; Robert C Edgar; Thilo Eickhorst; Ruth E Ley; Philip Hugenholtz; Susannah Green Tringe; Jeffery L Dangl
Journal: Nature Date: 2012-08-02 Impact factor: 49.962

10. Overcoming preexisting humoral immunity to AAV using capsid decoys.

Authors: Federico Mingozzi; Xavier M Anguela; Giulia Pavani; Yifeng Chen; Robert J Davidson; Daniel J Hui; Mustafa Yazicioglu; Liron Elkouby; Christian J Hinderer; Armida Faella; Carolann Howard; Alex Tai; Gregory M Podsakoff; Shangzhen Zhou; Etiena Basner-Tschakarjan; John Fraser Wright; Katherine A High
Journal: Sci Transl Med Date: 2013-07-17 Impact factor: 17.956

5 in total

Nature Biotechnology's academic spinouts of 2013.

1. Super-enhancers in the control of cell identity and disease.

2. Inhibitor mediated protein degradation.

3. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

4. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

5. Selective inhibition of tumor oncogenes by disruption of super-enhancers.

6. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.

7. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.

8. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

9. Defining the core Arabidopsis thaliana root microbiome.

10. Overcoming preexisting humoral immunity to AAV using capsid decoys.

Review 1. SCF ubiquitin ligase-targeted therapies.

Review 2. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

3. Nature Biotechnology's academic spinouts of 2014.

4. Epic $12 billion deal and FDA's approval raise CAR-T to new heights.

Review 5. Induced protein degradation: an emerging drug discovery paradigm.